Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PEPD | P12955 | 2/20 | 0.47 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2636058 | 1.00 | POLB (0.52) | POLBALDH1A1FKBP1ALMNARAB9A | |
| SCHEMBL5097555 | 0.95 | FKBP1A (0.56) | POLBALDH1A1FKBP1ALMNARAB9A | |
| SCHEMBL2770377 | 0.90 | FKBP1A (0.42) | POLBALDH1A1FKBP1ALMNARAB9A | |
| SCHEMBL7333530 | 0.85 | POLB (0.54) | POLBALDH1A1FKBP1ALMNARAB9A | |
| SCHEMBL4179454 | 0.85 | FKBP1A (0.55) | POLBALDH1A1FKBP1ALMNARAB9A | |
| SCHEMBL7333522 | 0.85 | POLB (0.54) | POLBALDH1A1FKBP1ALMNARAB9A | |
| SCHEMBL13662643 | 0.85 | FKBP1A (0.55) | POLBALDH1A1FKBP1ALMNARAB9A | |
| SCHEMBL23135776 | 0.83 | ALDH1A1 (0.54) | POLBALDH1A1FKBP1ALMNARAB9A | |
| SCHEMBL5491765 | 0.83 | LMNA (0.54) | POLBALDH1A1FKBP1ALMNARAB9A | |
| SCHEMBL683797 | 0.83 | POLB (0.52) | POLBALDH1A1FKBP1ALMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109251211-B | Quinolone carboxylic acid compound and intermediate thereof, preparation method and application | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | 2025-03-07 | — | — | CN | disclosed |
| CN-115650984-A | Preparation method of anagliptin | 江苏君若药业有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-106674254-B | Quinolone carboxylic acid compounds and intermediates, preparation method and application thereof | 广东省中医院 | 2019-03-15 | — | — | CN | disclosed |
| CN-109251211-A | A kind of quinolonecarboxylic acid compound and its intermediate, preparation method and application | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | 2019-01-22 | — | — | CN | disclosed |
| CN-106674254-A | Quinolone carboxylic acid compounds and intermediates, preparation method and application thereof | 广东省中医院 | 2017-05-17 | — | — | CN | disclosed |
| EP-3110795-A1 | NOVEL ECONOMIC PROCESS FOR VILDAGLIPTIN | Hikal Limited (IN) | 2017-01-04 | — | — | EP | disclosed |
| CN-106029635-A | Novel economic process for vildagliptin | 海蔻有限公司 | 2016-10-12 | — | — | CN | disclosed |
| WO-2015128718-A1 | NOVEL ECONOMIC PROCESS FOR VILDAGLIPTIN | HIKAL LIMITED (IN) | 2015-09-03 | — | — | WO | disclosed |
| US-8796454-B2 | Synthesis of [2.2.2]-diazabicyclic ring systems | COLLEGE OF WILLIAM AND MARY (US) | 2014-08-05 | — | — | US | disclosed |
| US-20130296564-A1 | SYNTHESIS OF [2.2.2]-DIAZABICYCLIC RING SYSTEMS | COLLEGE OF WILLIAM AND MARY (US) | 2013-11-07 | — | — | US | disclosed |
| US-8097618-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2012-01-17 | — | — | US | disclosed |
| US-20110190276-A1 | Pyridine Derivatives And Their Use In The Treatment Of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2011-08-04 | — | — | US | disclosed |
| EP-2336136-A1 | Pyridine derivatives and their use in the treatment of psychotic disorders | GlaxoSmithKline LLC (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2007028654-A1 | PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190276-A1 | Pyridine Derivatives And Their Use In The Treatment Of Psychotic Disorders | NDUFB7, NDUFB6, GABRE | POLB 2084/4885ALDH1A1 337/4885FKBP1A 768/4885 |
| US-20130296564-A1 | SYNTHESIS OF [2.2.2]-DIAZABICYCLIC RING SYSTEMS | BRD2, AZI2, CNDP2 | POLB 3614/4885ALDH1A1 260/4885FKBP1A 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.